|
|
Volumn 10, Issue 3, 2004, Pages 160-164
|
|
ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOTENSIN RECEPTOR ANTAGONIST;
BENZIMIDAZOLE DERIVATIVE;
CANDESARTAN;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
TETRAZOLE DERIVATIVE;
ARTICLE;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
CONGESTIVE HEART FAILURE;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COUGHING;
DRUG TOLERANCE;
HEART LEFT VENTRICLE FUNCTION;
HUMAN;
HYPOTENSION;
KIDNEY FAILURE;
MORTALITY;
RANDOMIZED CONTROLLED TRIAL;
TREATMENT OUTCOME;
ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS;
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
BENZIMIDAZOLES;
COUGH;
DRUG TOLERANCE;
HEART FAILURE, CONGESTIVE;
HUMANS;
HYPOTENSION;
KIDNEY FAILURE;
TETRAZOLES;
TREATMENT OUTCOME;
VENTRICULAR DYSFUNCTION, LEFT;
|
|
EID: 4344701964
PISSN: 15275299
EISSN: None
Source Type: Journal
DOI: 10.1111/j.1527-5299.2004.02806.x Document Type: Article |
|
Times cited : (14)
|
|
References (0)
|
